Literature DB >> 22833498

Discordant antibiotic therapy and length of stay in children hospitalized for urinary tract infection.

Karen E Jerardi1, Katherine A Auger, Samir S Shah, Matthew Hall, Paul D Hain, Angela L Myers, Derek J Williams, Joel S Tieder.   

Abstract

BACKGROUND: Urinary tract infections (UTIs) are a common reason for pediatric hospitalizations.
OBJECTIVE: To determine the effect of discordant antibiotic therapy (in vitro nonsusceptibility of the uropathogen to initial antibiotic) on clinical outcomes for children hospitalized for UTI. DESIGN/
SETTING: Multicenter retrospective cohort study in children aged 3 days to 18 years, hospitalized at 5 children's hospitals with a laboratory-confirmed UTI. Data were obtained from medical records and the Pediatric Hospital Information System (PHIS) database. PARTICIPANTS: Patients with laboratory-confirmed UTI. MAIN EXPOSURE: Discordant antibiotic therapy. MEASUREMENTS: Length of stay and fever duration. Covariates included age, sex, insurance, race, vesicoureteral reflux, antibiotic prophylaxis, genitourinary abnormality, and chronic care conditions.
RESULTS: The median age of the 216 patients was 2.46 years (interquartile range [IQR]: 0.27, 8.89) and 25% were male. The most common causative organisms were E. coli and Klebsiella species. Discordant therapy occurred in 10% of cases and most commonly in cultures positive for Klebsiella species, Enterobacter species, and mixed organisms. In adjusted analyses, discordant therapy was associated with a 1.8 day (95% confidence interval [CI]: 1.5, 2.1) longer length of stay [LOS], but not with fever duration.
CONCLUSIONS: Discordant antibiotic therapy for UTI is common and associated with longer hospitalizations. Further research is needed to understand the clinical factors contributing to the increased LOS and to inform decisions for empiric antibiotic selection in children with UTIs.
Copyright © 2012 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833498     DOI: 10.1002/jhm.1960

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  6 in total

1.  Single-stage versus multi-stage pull-through for Hirschsprung's disease: practice trends and outcomes in infants.

Authors:  Jason P Sulkowski; Jennifer N Cooper; Anthony Congeni; Erik G Pearson; Benedict C Nwomeh; Edward J Doolin; Martin L Blakely; Peter C Minneci; Katherine J Deans
Journal:  J Pediatr Surg       Date:  2014-07-10       Impact factor: 2.545

2.  Impact of Third-Generation Cephalosporin Resistance on Recurrence in Children with Febrile Urinary Tract Infections.

Authors:  Sin Young Kim; Min Sik Jang; Jihye Kim
Journal:  J Pers Med       Date:  2022-05-10

3.  Antimicrobial Resistance or Delayed Appropriate Therapy-Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?

Authors:  Thomas P Lodise; Ariel Berger; Arman Altincatal; Rosa Wang; Tarun Bhagnani; Patrick Gillard; Nicole G Bonine
Journal:  Open Forum Infect Dis       Date:  2019-04-23       Impact factor: 3.835

Review 4.  Current status of long-term antibiotic prophylaxis for urinary tract infections in children: An antibiotic stewardship challenge.

Authors:  Sarah S Alsubaie; Mazin A Barry
Journal:  Kidney Res Clin Pract       Date:  2019-12-31

5.  Clinical Outcome of Discordant Empirical Therapy and Risk Factors Associated to Treatment Failure in Children Hospitalized for Urinary Tract Infections.

Authors:  Giovanni Autore; Cosimo Neglia; Margherita Di Costanzo; Martina Ceccoli; Gianluca Vergine; Claudio La Scola; Cristina Malaventura; Alice Falcioni; Alessandra Iacono; Antonella Crisafi; Lorenzo Iughetti; Maria Luisa Conte; Luca Pierantoni; Claudia Gatti; Giacomo Biasucci; Susanna Esposito
Journal:  Children (Basel)       Date:  2022-01-19

6.  Aetiologies and Risk Factors of Prolonged Fever Admission in Samtse Hospital, Bhutan, 2020.

Authors:  Tsheten Tsheten; Karma Lhendup; Thinley Dorji; Kinley Wangdi
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.